

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/694,074	10/20/2000	Rebecca J. Jackman	H0498/7085 TJO	2002
75	90 07/26/2006		EXAMINER	
Timothy J. Oyer Wolf, Greenfield & Sacks, P.C.			PARKER, FREDERICK JOHN	
600 Atlantic Av			ART UNIT PAPER NUMBER	
Boston, MA (02210		1762	
			DATE MAILED: 07/26/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/694,074	JACKMAN ET AL.				
Before the Filing of an Appeal Brief	Examiner	Art Unit				
	Frederick J. Parker	1762				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 10 July 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3)						
a Request for Continued Examination (RCE) in compliand time periods:	ce with 37 CFR 1.114. The reply mu	ust be filed within one	of the following			
 a)						
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).						
<u>AMENDMENTS</u>						
 The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); 						
(b) They raise the issue of new matter (see NOTE below);						
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.				
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).						
5. Applicant's reply has overcome the following rejection(s):						
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE						
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).						
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a						
showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER						
 The request for reconsideration has been considered bu <u>See Continuation Sheet.</u> 	it does NOT place the application in	n condition for allowar	nce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).						
13.		\mathcal{A}				
	L	Frederick J. Parker Frimary Examiner Ax Unit: 1762				

Continuation of 11. does NOT place the application in condition for allowance because: the remarks are related to the affidavit of Klavs Jensen who admits having an interest in the issuance of the patent aplicaytion at yhand. Thus, the affidavit does not provide unbiased evidence or support for the record as previously suggested in the Examiner's Final OA. Applicants opine the stated the PTO interpretation of "biological agent" is inconsistent with that of the specification. It is noted by the Examiner 's statement that the specification never DEFINES the meaning of biological agent remains uncontested, instead Applicants relying on examples in place of a specific meaning. Interesting is Prof. jensen's wording of the Affidavit wherein it is stated: "... the specification illustates a protein..."; and ""biological agents" may have a native form or biological binding partners". :May have or "illustrate" are not definition and only provide potential examples, which in context of the specification are not limited, further supporting the Examier's position. The Examiner provided a simple suggestion to overcome the prior art rejection while claiming the intended invention in the previous Office Action, subject to update search. It is respectfully requested Applicants reconsider the suggestion.